10 AbbVie executives
AbbVie executives in current roles here include the Chairman and CEO, the CFO, the Chief Operations Officer and the General Counsel, plus senior vice presidents whose titles name Oncology, Neuroscience, Global Allergan Aesthetics, International and Specialty and U.S. Therapeutics. Biotechs weighing a licensing deal, investors studying the portfolio and suppliers selling into a large drugmaker can each find the executive who owns that decision area.
Professionals to explore
Azita Saleki, Ph.D.
LinkedInExperience: Executive Vice President, Chief Operations Officer · AbbVie
Azita Saleki, Ph.D., has been Executive Vice President, Chief Operations Officer at AbbVie since 2012, leading a global team of scientific, manufacturing, engineering, quality and supply chain professionals. The team is responsible for supply and distribution of all AbbVie products, which makes this the call on manufacturing capacity and supply partners.
Is this you? Claim your profile and get paid for calls.
Jason Smith
LinkedInExperience: SVP, AbbVie, and President, Neuroscience · AbbVie
In neuroscience, Jason Smith has been SVP, AbbVie, and President, Neuroscience since February 2026, following SVP and Head of Europe Commercial Operations (2024-2026) and SVP and President, Allergan Aesthetics International (2020-2024) at AbbVie. SVP and President, Asia Pacific, Middle East and Africa at Allergan (2017-2020) and Head of Asia Cluster at Novartis (2015-2017) add regional commercial experience.
Is this you? Claim your profile and get paid for calls.
Jerome Bouyer
LinkedInExperience: Former SVP AbbVie & President International · AbbVie
Jerome Bouyer became SVP AbbVie & President International in January 2026, after SVP AbbVie & President Immunology (2024-2026) and SVP AbbVie & President Europe (2022-2024). Area Vice President- EEMEA (2019-2022) and VP & General Manager United Kingdom (2017-2019) make Jerome Bouyer a fit for commercial questions outside the US.
Is this you? Claim your profile and get paid for calls.
Mitchell Brin
LinkedInExperience: Sr. VP R&D & Chief Scientific Officer, BOTOX & Neurotoxins · AbbVie
Mitchell Brin is Sr. VP R&D & Chief Scientific Officer, BOTOX & Neurotoxins at AbbVie since May 2020, and also lists Sr. VP Global Drug Development & Chief Scientific Officer, BOTOX at Allergan since 2007. Allergan development roles as Sr. VP (2004-2007) and VP (2001-2004) make this the R&D voice for neurotoxin development and clinical programs.
Is this you? Claim your profile and get paid for calls.
Nicole Mowad-Nassar
LinkedInExperience: Senior Vice President, AbbVie and President, Global Allergan Aesthetics · Allergan Aesthetics, an AbbVie Company
Nicole Mowad-Nassar leads the aesthetics business as Senior Vice President, AbbVie and President, Global Allergan Aesthetics since September 2025, and also sits on the Board of Directors of Resmed. Senior Vice President, AbbVie and President, Specialty and U.S. Therapeutics Operations (2023-2025), commercial analytics and operations VP roles at AbbVie (2018-2023) and a U.S. business operations and external partnerships role at Takeda (2016-2017) fit partnership questions.
Is this you? Claim your profile and get paid for calls.
Nisha Patel Burns
LinkedInExperience: Senior Vice President, AbbVie and President, Specialty and U.S. Therapeutics Operations · AbbVie
Senior Vice President, AbbVie and President, Specialty and U.S. Therapeutics Operations since September 2025, Nisha Patel Burns previously held Vice President roles in International Marketing and Commercial Operations (2023-2025), Global Marketing, Immunology (2021-2023), US Gastroenterology (2019-2021) and Immunology, Global Commercial Development (2017-2019) at AbbVie, a strong fit for immunology commercial questions.
Is this you? Claim your profile and get paid for calls.
Perry Siatis
LinkedInExperience: Executive Vice President, General Counsel and Secretary · AbbVie
As Executive Vice President, General Counsel and Secretary at AbbVie since October 2022, Perry Siatis also held Senior Vice President, Deputy General Counsel (2021-2022), Senior Vice President, Legal, Chief Ethics and Compliance Officer (2019-2021) and Vice President, Biotherapeutics & Legal covering global commercial, M&A licensing and privacy (2013-2019). Licensing, compliance and governance questions fit best here.
Is this you? Claim your profile and get paid for calls.
Rob Michael
LinkedInExperience: Chairman of the Board and Chief Executive Officer · AbbVie
Rob Michael is Chairman of the Board and Chief Executive Officer of AbbVie since July 2025, after Chief Executive Officer (2024-2025), President and Chief Operating Officer (2023-2024), Vice Chairman and President (2022-2023) and Vice Chairman, Finance and Commercial Operations and Chief Financial Officer (2021-2022). Having held the CFO, COO and CEO seats, Rob Michael fits questions on company-level portfolio and investment choices.
Is this you? Claim your profile and get paid for calls.
Scott Reents
LinkedInExperience: Executive Vice President, Chief Financial Officer · AbbVie
Executive Vice President, Chief Financial Officer at AbbVie since November 2022, Scott Reents describes responsibility for global financial and business technology operations. Senior Vice President, Chief Financial Officer (2022), Vice President, Tax and Treasury (2019-2022) and Vice President, Tax (2013-2019) add tax and treasury depth, useful for deal structure and financing questions.
Is this you? Claim your profile and get paid for calls.
Wulff-Erik von Borcke
LinkedInExperience: Senior Vice President, AbbVie, and President, Oncology · AbbVie
Wulff-Erik von Borcke holds three current oncology roles: Senior Vice President, AbbVie, and President, Oncology since July 2023, President, US Oncology since 2020, and President at Pharmacyclics, an AbbVie Company since 2015. Vice President Global Marketing at AbbVie (2013-2015) and Divisional Vice President, Global Marketing, Pharmaceuticals at Abbott (2011-2012) complete the record.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Questions about capital allocation and acquisitions belong with Rob Michael or Scott Reents, deal terms and governance with Perry Siatis, and manufacturing and supply with Azita Saleki. For a specific therapeutic area, go to the matching leader: Wulff-Erik von Borcke for oncology, Jason Smith for neuroscience, Nicole Mowad-Nassar or Mitchell Brin for aesthetics and neurotoxins, and Jerome Bouyer or Nisha Patel Burns for international and U.S. commercial questions.
Questions to take into the conversation
- 01What does a biotech need to show AbbVie's business development and therapeutic area leaders before a licensing or acquisition conversation moves forward?
- 02How does a large drugmaker plan for revenue loss when a major product loses exclusivity?
- 03How does an aesthetics business inside a pharmaceutical company differ from the prescription drug business in sales, marketing and pricing?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.